Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology for Diamond-Blackfan Anemia

Fulcrum Therapeutics Secures Exclusive Global License Agreement in Rare Hematology &nbsp In a significant development, Fulcrum Therapeutics, Inc. has recently announced the signing of an exclusive worldwide license agreement with CAMP4 Therapeutics Corp. The objective of this partnership is to advance the discovery, development, and commercialization of innovative therapeutic solutions for Diamo..

  • format_list_bulleted BS
  • · 2023. 7. 11.
  • textsms

Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics is preparing to begin Phase II and first-in-human trials later in 2023 with two Orphan Drug Designations, an advantageous safety profile, and enhanced therapeutic indices. The company's pipeline uses their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine to identify candidate molecules with improved therapeutic indices and the ability to penetrate ..

  • format_list_bulleted BS
  • · 2023. 6. 26.
  • textsms